Moleculin Biotech (MBRX) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[3], including 1 Phase 3[1], 1 Phase 2[2].
Trial NCT06788756[4] evaluates Placebo in combination with Cytarabine Injection in Acute Myeloid Leukaemia (AML) with a target enrollment of 312 participants.
No Form 4 insider filings for MBRX were recorded at the SEC in the past 30 days[5].